Innovate UK

Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™ Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claims substantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. And it’s all done in vivo! Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com) Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, CSB, and is a resident company of Johnson & Johnson Innovation – JLABS. Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo.

DRG labs at Ulster, maintain full access to the cutting-edge facilities on-site and its connection to a group of scholars and experts in diseases. Afterward, lead molecules for animal research are identified by advancing therapeutic candidates through our discovery platform, which uses industry-standard methodologies and models.

Epitopea is a biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a new class of tumor-specific antigens. The company employs a proprietary approach that combines immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's non-coding DNA. This technology aims to create therapies that effectively eliminate malignant cells while minimizing damage to healthy tissue, thereby reducing side effects and providing lasting benefits for patients. Research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal has been instrumental in the discovery of these novel antigens, known as Cryptigen™ TSAs, which are shared among patients with the same cancer type.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

LIfT BioSciences is a biotechnology company based in London, England, founded in 2016. The company specializes in a novel allogeneic innate immuno-cell therapy platform known as Neutrophil Only Leukocyte Infusion Therapy (N-LIfT). This platform enables the large-scale production of Immunomodulatory Alpha Neutrophils (IMANs) derived from induced pluripotent stem cells (iPSCs) for various therapeutic applications. LIfT BioSciences focuses on developing CAR neutrophil cell therapies that address the limitations of existing treatments for solid tumors. These therapies work by directly attacking tumors and indirectly enhancing the immune response, effectively transforming the tumor microenvironment to recruit additional immune cells for a more robust and lasting attack on the cancer. By employing proprietary enhancement media and genetic engineering, LIfT BioSciences aims to significantly increase the cancer-fighting capabilities of these engineered cells, potentially providing patients with greatly improved therapeutic outcomes.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

Presymptom Health develops a portfolio of clinical decision support algorithms and blood tests to enable early intervention and transform critical care outcomes.

IXICO is a UK-based company specializing in clinical trial services and technology focused on imaging endpoints for the pharmaceutical and biotechnology sectors. The company primarily operates in the fields of oncology and neurology, offering end-to-end imaging services that cater to various therapeutic areas, including Alzheimer's, Parkinson's, Huntington's disease, and other neurodegenerative conditions. IXICO supports clients throughout the entire clinical research journey, providing services for early and late-phase clinical development, post-marketing assessments, and consultancy. With a presence in multiple countries, including the United States, Switzerland, the Netherlands, and Ireland, IXICO collaborates with pharmaceutical companies, academia, and medical charities to advance the treatment of complex diseases.

Aelius Biotech specializes in creating advanced models of the mucosal surfaces of the human body. The company focuses on developing systems that simulate the gastrointestinal tract and airways, with ongoing efforts to model the eye and cervico-vaginal tract. Aelius Biotech's model gut system allows healthcare industry participants to simulate essential processes such as digestion, mucus permeation, and epithelial absorption. The company provides a range of testing services, including in vitro and in vivo assessments, simple lab assays, and integrated model gut testing across the aerodigestive tract. Additionally, Aelius Biotech conducts human trials, aiding healthcare companies in making informed, data-driven decisions to enhance and de-risk the development of orally delivered products.

PulmoBiomed is a developer of innovative sampling technology that offers a non-invasive method for clinicians and researchers to collect biological samples. The company's primary product is a passive fluid aerosol sampler designed to capture exhaled breath condensate and environmental particles, effectively segregating them by size. This technology addresses critical challenges in sample collection, such as preventing contamination and loss, while ensuring the generation of highly reproducible data with digital molecular precision. By focusing on metabolomic profiling and biological agent capture, PulmoBiomed aims to enhance the accuracy and reliability of respiratory diagnostics and research.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

Physiomics plc combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company’s lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical and clinical trials. This optimisation improves the efficacy of combinations and streamlines the drug development process.

Stablepharma Ltd specializes in developing innovative processes for vaccine stabilization, focusing on its technology platform, StablevaX™, which transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This advancement addresses the global challenges associated with cold chain logistics, allowing for efficient and waste-free vaccine delivery. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates with global vaccine manufacturers, academic institutions, and non-governmental organizations to enhance its pipeline of thermostable products. Founded in 2012 and based in Bath, United Kingdom, Stablepharma aims to reduce costs and carbon emissions while expanding access to vaccines for both children and adults.

ZiO Health is a biotechnology company that focuses on transforming laboratory testing through its proprietary pocket-sized technology, which allows for point-of-care diagnostics. By combining advanced biosensor technology with machine learning algorithms, ZiO Health provides real-time testing results tailored to each patient's unique profile. This innovative approach enables users to measure, test, and detect the molecular composition of various substances, facilitating personalized health insights. The company's devices aim to optimize health management and enhance patient outcomes, allowing individuals to conduct quality home diagnostics and take proactive steps in preventing illness.

Ramanomics extracts microorganisms and their antimicrobial profiles from clinical specimens.

Kalium Health Ltd is a company focused on improving kidney care through innovative medical technology. Based in Cambridge, United Kingdom, it designs and manufactures a finger-prick blood test specifically for measuring blood potassium concentration. This test aims to facilitate early treatment for patients, reducing the complications and costs associated with traditional testing methods. By leveraging advanced electrolyte sensing technology, Kalium Health provides patients with accurate, real-time data essential for managing cardiorenal diseases. The company’s first product addresses a significant risk in kidney disease, a condition that imposes substantial financial burdens on healthcare systems. With a clear regulatory pathway and a targeted market strategy, Kalium Health is poised to transform patient care and enhance outcomes for millions affected by kidney disease.

The Cell and Gene Therapy Catapult is a UK-based center dedicated to fostering innovation in the cell and gene therapy sector. Supported by Innovate UK, its primary objective is to accelerate the development of commercially viable therapies by assisting organizations in translating early-stage research into market-ready products. The Catapult employs over 120 experts in cell and gene therapy and features advanced laboratories for development and viral vector research. Additionally, it is in the process of establishing a £55 million large-scale Good Manufacturing Practice (GMP) manufacturing center to facilitate the market introduction of cell and gene therapies both in the UK and internationally. By offering expertise in clinical trials, process development, manufacturing, regulatory affairs, health economics, and market access, the Catapult aims to help research organizations achieve full-scale commercialization of their therapies.

Autolomous Ltd, founded in 2019 and based in Mayfair, United Kingdom, specializes in developing software solutions for manufacturers of cell and gene therapies. Its flagship platform, autoloMATE®, is a cloud-native system that provides comprehensive support for Advanced Therapies and Vector manufacturing processes. The software facilitates the scheduling of patient cell collections, the transport of these cells to production sites, and the tracking of manufacturing processes to ensure compliance with regulatory standards. It also supports the legal release and timely delivery of patient-specific medicines. The highly configurable platform allows clients to customize workflows and integrates seamlessly with existing systems. Autolomous emphasizes data security by utilizing blockchain technology to maintain the integrity of manufacturing data. The company adheres to strict regulatory guidelines and has achieved several ISO certifications, reflecting its commitment to quality management and environmental standards.

Neu Health develops a smartphone-based clinical platform designed to deliver personalized care for individuals with Parkinson's disease and dementia. Utilizing cutting-edge digital technologies and artificial intelligence, the platform monitors and interprets digital indicators of clinically relevant symptoms. This approach aims to enhance condition management, alleviate the workload on clinicians, and ultimately improve patient outcomes. By enabling clinicians and caregivers to provide more efficient and effective care, Neu Health addresses the growing challenges faced by those managing these complex neurological conditions.

Lindus Health is a clinical research organization focused on delivering comprehensive clinical trial services for health and biotech companies. The company offers a range of solutions, including ethics and IRB submission, trial monitoring, data management, biostatistics, regulatory support, and payer affairs. By utilizing a proprietary software platform, Lindus Health automates various aspects of the clinical trial workflow, which streamlines operations and minimizes manual inefficiencies. This platform also facilitates access to electronic health records, enhancing patient recruitment and clinical data capture. Furthermore, Lindus Health leverages real-world patient data to improve trial design and execution, ultimately aiming to accelerate the clinical trial process while reducing risks and costs associated with trial failures.

Senisca is a biotech start-up. They propose to create a new generation of oligonucleotide-based interventions to rewind the clock in old cells and target diseases and cosmetic signs of aging. They provide molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to extend the life expectancy of glioblastoma patients, a group historically faced with limited treatment options and poor survival rates. Recognizing the urgent need for effective therapies, co-founders Dr. Richard Fu and Dr. Chris Bullock created a solution to address both the clinical and quality of life challenges faced by patients. The company has garnered nearly $1 million in funding from UK institutions, including Innovate UK, and over $1 million in equity funding from international life science investors. With a multidisciplinary team based in Alderley Park, Cheshire, QV Bioelectronics is dedicated to advancing GRACE from research to clinical application, utilizing cutting-edge materials science to enhance treatment outcomes for patients.

GenoME Diagnostics is a biotechnology company focused on improving cancer detection through advanced blood testing technology. The company has developed the OvaME product, which enhances the standard CA125 blood tests, providing earlier detection and more accurate diagnoses of various cancers. By utilizing innovative techniques, GenoME Diagnostics aims to minimize misdiagnosis and reduce the likelihood of late detection, thereby enabling healthcare professionals to diagnose and treat patients more effectively.

Myma Medical is a bright, cutting-edge start-up with a model to greatly improve the experiences of people who are having fertility issues.

The National Biofilms Innovation Centre (NBIC) is the central hub where academia, industry, government, and public policy come together to tackle the grand challenges biofilms present, impacting ~$5 trillion in global economic activity, from food and health to ships, clean water and energy. Funded by the BBSRC, Innovate UK and Hartree Centre, our mission is to establish a network of research and innovation capacity to catalyse partnerships with industry to achieve breakthrough innovations and impact – from industry products and solutions to services and spinouts. We aim to bring together researchers and industry to explore unmet needs and exchange ideas, problems and solutions through roadmaps, workshops and conferences. We plan to invest in future scientists through our PhD and Post-Doc programs, and entrepreneurial training, to grow their expertise, help them better understand the commercial environment and encourage new start-ups.

Enhanced Fertility addresses the significant challenge of infertility, which affects one in six couples worldwide, with less than 2% able to access necessary care. The company employs data, artificial intelligence, and remote diagnostics to improve clinical decision-making for fertility clinics. By streamlining the patient pathway, Enhanced Fertility reduces the time to treatment from three years to just 30 days. Their approach includes at-home testing and AI-enabled care, enabling clinicians to make informed decisions that increase the likelihood of achieving a live birth for patients.

LabGenius Ltd is a biopharmaceutical company based in London that focuses on discovering new biological molecules through the integration of artificial intelligence, automation, and synthetic DNA. Founded in 2012, the company has developed a robotic platform known as EVA, which acts as a robot scientist capable of designing, conducting, and learning from its own experiments. LabGenius specializes in developing next-generation protein therapeutics aimed at addressing unmet medical needs, including conditions like Inflammatory Bowel Disease. Their innovative approach utilizes advanced machine learning and synthetic biology to engineer the properties of protein drugs, enhancing attributes such as protease stability and tissue penetration. This technology enables the efficient creation of protein therapeutics, providing physicians with access to cutting-edge treatments developed through robotic automation.

ProtonDx is a diagnostic platform specializing in molecular testing services that focus on detecting and differentiating multiple pathogens from patient samples. The company develops point-of-care diagnostic test devices that aid healthcare professionals in diagnosing infectious diseases using innovative handheld technology. By integrating advanced microchip technology with molecular biology and machine learning, ProtonDx offers rapid, sensitive, and specific testing solutions that can be deployed in hospital settings. This capability allows healthcare organizations to efficiently manage clinical cases and monitor infectious disease outbreaks in real-time. Customer inquiries can be addressed through contact forms and email.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™ Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claims substantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. And it’s all done in vivo! Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com) Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, CSB, and is a resident company of Johnson & Johnson Innovation – JLABS. Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo.

Senisca is a biotech start-up. They propose to create a new generation of oligonucleotide-based interventions to rewind the clock in old cells and target diseases and cosmetic signs of aging. They provide molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence.

NRG Therapeutics is a drug discovery company established in 2018 that specializes in developing therapeutic approaches aimed at restoring mitochondrial function to address neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, and motor neuron disease. The company focuses on creating novel medicines that preserve mitochondrial function and halt disease progression. With a team experienced in neuroscience drug discovery, NRG Therapeutics is initially concentrating on the discovery and development of brain-penetrant inhibitors of the mitochondrial permeability transition pore specifically for Parkinson’s disease. This strategic focus is intended to empower physicians with effective treatment options for patients suffering from chronic neurodegenerative disorders.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

Enhanced Fertility addresses the significant challenge of infertility, which affects one in six couples worldwide, with less than 2% able to access necessary care. The company employs data, artificial intelligence, and remote diagnostics to improve clinical decision-making for fertility clinics. By streamlining the patient pathway, Enhanced Fertility reduces the time to treatment from three years to just 30 days. Their approach includes at-home testing and AI-enabled care, enabling clinicians to make informed decisions that increase the likelihood of achieving a live birth for patients.

GenoME Diagnostics is a biotechnology company focused on improving cancer detection through advanced blood testing technology. The company has developed the OvaME product, which enhances the standard CA125 blood tests, providing earlier detection and more accurate diagnoses of various cancers. By utilizing innovative techniques, GenoME Diagnostics aims to minimize misdiagnosis and reduce the likelihood of late detection, thereby enabling healthcare professionals to diagnose and treat patients more effectively.

Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.

CryoLogyx is an early-stage biotechnology company focused on advancing cell cryopreservation technology to enhance drug discovery processes. By employing innovative methods that utilize cryoprotectants, CryoLogyx transforms the freezing, storage, and transportation of cells. This proprietary technology ensures the delivery of viable, ready-to-use cells and cell therapies, allowing healthcare researchers to access these resources in the desired format. The company's approach aims to improve the efficiency and effectiveness of cell-based research in the fields of medicine discovery, diagnostics, and cell therapy.

Senisca is a biotech start-up. They propose to create a new generation of oligonucleotide-based interventions to rewind the clock in old cells and target diseases and cosmetic signs of aging. They provide molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence.

Camallergy Limited, based in Cambridge, United Kingdom, is a biopharmaceutical company established in 2015 that focuses on developing and manufacturing oral immunotherapy drugs and other pharmaceutical products specifically for food allergies. The company's primary offering is a novel oral immunotherapy designed to treat peanut allergies, which aims to provide patients with "bite-proof" protection within 14 weeks of therapy. This patient-centric treatment addresses the urgent needs of millions suffering from food allergies and is rooted in clinical research conducted at Cambridge University Hospitals NHS Foundation Trust. Camallergy's unique intellectual property and treatment regimen exemplify its commitment to improving the quality of life for individuals affected by these allergies.

CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based on the culture of primary human hepatocytes in the company’s proprietary LiverChip platform. The HBV disease model, which is referred to as Quantum-B, is currently being deployed in drug discovery and research alliances with several leading pharmaceutical and biotech companies. Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next-generation organ-on-chips which will improve the quality of life for millions of people around the world by fast-tracking breakthrough therapies to market.

IgniteData is a technology company focused on transforming clinical trials through its cloud-based virtual research assistant, Archer. This solution serves as a global electronic health record (EHR) to electronic data capture (EDC) platform, facilitating secure transmission of clinical data. By automating patient recruitment and enhancing real-world evidence processes, IgniteData enables researchers to efficiently collect trial data and accelerate study timelines. The company's innovations aim to improve the quality of clinical research while reducing the workloads for clients, ultimately helping to deliver critical therapies to patients more swiftly.

NovaBiotics Ltd. is a clinical-stage biotechnology company based in Aberdeen, United Kingdom, with an additional location in Raleigh, North Carolina. Founded in 2004, the company specializes in the design and development of innovative anti-infective therapies for medically unmet diseases. Its product pipeline includes Novexatin, a cationic antifungal peptide for treating onychomycosis, and Lynovex, a dual-therapy for cystic fibrosis-related lung diseases. Additionally, NovaBiotics offers other antifungal peptides such as Novamycin for conditions like aspergillosis and cryptococcosis, as well as Novarifyn, an antibacterial peptide targeting bacterial infections. The company’s proprietary anti-infective peptide platform allows for the development of both antifungal and antibacterial candidates, addressing serious health challenges related to drug-resistant infections.

Reflection Therapeutics is developing cell therapy technology against neuroinflammation across the board.

Albus Health, a startup emerging from the University of Oxford, has created an intelligent nocturnal monitoring platform designed for personalized home use. This system facilitates passive, contactless, and objective monitoring of various symptoms and environmental metrics, making it particularly useful for assessing nocturnal conditions. The platform has been successfully commercialized and is currently employed by leading pharmaceutical companies to monitor nocturnal symptoms during clinical trials. Additionally, it has the capability to predict respiratory emergencies, thus enhancing patient safety and outcomes.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to extend the life expectancy of glioblastoma patients, a group historically faced with limited treatment options and poor survival rates. Recognizing the urgent need for effective therapies, co-founders Dr. Richard Fu and Dr. Chris Bullock created a solution to address both the clinical and quality of life challenges faced by patients. The company has garnered nearly $1 million in funding from UK institutions, including Innovate UK, and over $1 million in equity funding from international life science investors. With a multidisciplinary team based in Alderley Park, Cheshire, QV Bioelectronics is dedicated to advancing GRACE from research to clinical application, utilizing cutting-edge materials science to enhance treatment outcomes for patients.

Medwise.ai offers a customizable search platform designed to support clinical decision-making for healthcare professionals. Utilizing natural language processing and artificial intelligence, the platform enables doctors to efficiently access and organize medical knowledge. By leveraging real-world data, Medwise.ai provides valuable intelligence and insights to various stakeholders within the healthcare ecosystem. This innovative approach aims to enhance the professional capabilities of doctors, ultimately improving patient care and outcomes.

ONKO is a provider of unified cancer care. ONKO combines digital technology with the support of healthcare professionals to provide patients with personalised expertise from cancer dietitians, physiotherapists, specialist nurses and psychologists.

Neuronostics Ltd is a newly established University of Exeter (UK) spin-out, focussed on the development and commercialisation of a novel and potentially revolutionary seizure susceptibility assessment technology called #BioEP.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, based in Stirling, United Kingdom. Established in 2011 to address the growing global demand for niche sterile manufacturing, the company provides filling and finishing services tailored to biotechnology and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis differentiates itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. By maintaining high standards of regulatory compliance, Symbiosis supports the evolving needs of its clients in the pharmaceutical sector.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

LUNAC Therapeutics is focused on developing advanced oral anticoagulant medications aimed at treating and preventing serious thrombotic events. The company’s innovative drugs are designed to reduce the risk of bleeding in patients, which allows healthcare providers to safely escalate dosages for high-risk individuals. By addressing a critical need in the management of thrombotic conditions, LUNAC Therapeutics aims to improve patient outcomes and enhance the overall safety of anticoagulant therapies.

BrainWaveBank has developed a first-in-class wearable electroencephalography (EEG) device to conveniently and non-invasively measure the mechanisms that underpin neurological disorders and therapies. Our platform can securely gather, store and analyse data from many thousands of users, building neurocognitive profiles of individuals and populations or demographic groups. This easy-to-scale and distributable approach will help clinical professionals to transform our understanding of brain health and develop the next generation of treatments. BrainWaveBank was founded in January 2015 and has offices in Belfast , Northern Ireland and Dublin, Ireland.

Healum is a developer of connected software and applications aimed at enhancing self-management for individuals with long-term health conditions. The company's AI-powered platform offers personalized care and support by leveraging data-driven insights and evidence-based behavioral interventions. Healum's tools enable patients to effectively monitor and understand both their physical and mental health, while also providing healthcare professionals with the means to assist patients in managing chronic conditions. This approach promotes a collaborative environment where patients receive customized support tailored to their unique health needs.

Albus Health, a startup emerging from the University of Oxford, has created an intelligent nocturnal monitoring platform designed for personalized home use. This system facilitates passive, contactless, and objective monitoring of various symptoms and environmental metrics, making it particularly useful for assessing nocturnal conditions. The platform has been successfully commercialized and is currently employed by leading pharmaceutical companies to monitor nocturnal symptoms during clinical trials. Additionally, it has the capability to predict respiratory emergencies, thus enhancing patient safety and outcomes.

Freeline Therapeutics is a clinical-stage biotechnology company focused on developing innovative adeno-associated virus (AAV) vector-mediated gene therapies aimed at treating inherited systemic diseases. The company employs engineered AAV vectors and capsids, alongside novel promoters and transgenes, to introduce functional copies of therapeutic genes into human liver cells. This process allows for the production of essential proteins in the bloodstream, addressing deficiencies caused by genetic disorders. Freeline's key product candidates include FLT180a for hemophilia B, FLT190 for Fabry disease, and FLT201 for Gaucher disease Type 1. Their ongoing development programs encompass various clinical trials to advance these gene therapies and provide transformative solutions for patients suffering from debilitating conditions.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, based in Stirling, United Kingdom. Established in 2011 to address the growing global demand for niche sterile manufacturing, the company provides filling and finishing services tailored to biotechnology and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis differentiates itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. By maintaining high standards of regulatory compliance, Symbiosis supports the evolving needs of its clients in the pharmaceutical sector.

Digital consent (econsent) to treatment application transforming how we make decisions about our health. Decisions informed by patient outcomes, and shared by patient and clinician.

A UK pharmaceutical development company, AKL Research & Development Ltd (AKLRD) is committed to transforming patient’s lives through innovative solutions that meet unmet needs.AKLRD is developing novel therapeutics for inflammatory diseases with a high unmet need, including osteoarthritis, Alzheimer’s, rheumatoid arthritis & scleroderma, a rare connective tissue disease.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

MediSieve Ltd. is a medical device company based in London, United Kingdom, focused on developing Magnetic Blood Filtration (MBF) technology to treat blood-borne diseases. Established in 2014, the company has created a blood filtration device that magnetically removes infected blood cells, enabling the treatment of conditions such as malaria, leukemia, and sepsis. The MBF system operates by circulating a patient’s blood through an external loop where targeted magnetic particles bind to disease-relevant targets. The blood then passes through a magnetic filter that captures these particles and bound targets, allowing the unaffected blood to be returned to the patient. MediSieve's innovative approach also aims to enhance the safety and efficacy of existing therapies while expanding the range of treatable diseases. The company operates from the Imperial Incubator in White City, London, where it has specialized laboratory facilities for product development and validation.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. The company's flagship product, PredictSURE IBD, is a diagnostic tool that evaluates patients with inflammatory bowel disease, including Crohn's disease and ulcerative colitis. This test utilizes a small blood sample to identify patients at diagnosis who are at risk of severe, relapsing disease, thereby enabling healthcare providers to recommend early biologic therapy to those who would benefit most. By providing crucial prognostic information, PredictImmune aims to enhance treatment decision-making for physicians and improve outcomes for patients suffering from these conditions. The company's research is rooted in leading studies from Cambridge University, reflecting its commitment to advancing personalized medicine in the field of inflammatory bowel disease.

PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing nucleic acid therapeutics, particularly antisense oligonucleotides. Founded in 2018, the company aims to enhance the delivery and efficacy of these therapies through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative platform utilizes engineered peptides designed to improve tissue penetration, cellular uptake, and nuclear delivery of oligonucleotides. PepGen's technology has shown promise in preclinical studies, demonstrating the ability to transport therapeutics effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. The company's mission is to unlock the full potential of nucleic acid therapeutics to transform the treatment landscape for severe neuromuscular and neurological diseases.

RoslinCT is a UK-based contract development and manufacturing organization that specializes in supporting companies engaged in the development of cell-based therapeutic products. The company offers a range of services, including cell and gene therapy development, tissue procurement, cryopreservation studies, pre-clinical studies, and analytical development. By providing these comprehensive services, RoslinCT enables its clients to deliver compliant, sustainable, and affordable therapies to the market.

Medherant Limited is a clinical-stage company based in Coventry, United Kingdom, focused on developing innovative treatments for pain and central nervous system diseases through its advanced transdermal drug delivery technology. Founded in 2014 by Professor David Haddleton and the University of Warwick, Medherant has created the TEPI Patch, a novel transdermal system that utilizes a unique adhesive to enhance drug delivery while overcoming challenges associated with metabolism, gastrointestinal toxicity, and low bioavailability. Unlike traditional patch technologies that may have limited drug loading capacities, Medherant's approach allows for higher concentrations of medications and faster release rates. This method addresses the shortcomings of topical creams and gels, which often lack precise dose control, thereby providing an effective solution for delivering a broader range of pharmaceutical products.

Targeting pathways that modify RNA to deliver novel cancer therapeutics.

Neuronostics Ltd is a newly established University of Exeter (UK) spin-out, focussed on the development and commercialisation of a novel and potentially revolutionary seizure susceptibility assessment technology called #BioEP.

Metrion Biosciences Ltd is a contract research organization based in Cambridge, United Kingdom, specializing in drug discovery services for pharmaceutical and bioscience clients globally. Established in 2015, the company provides a range of preclinical screening services, with a focus on ion channel screening, cardiac safety profiling, neuroscience assays, and translational assays. Metrion's platform offers skilled electrophysiology services in various formats, supporting medicinal chemistry optimization. The organization employs flexible business models, allowing clients to choose between fee-for-service and collaborative options, as well as access to integrated drug discovery services tailored to the specific needs of each program.

Ubiquigent Limited is a biotechnology company based in Dundee, United Kingdom, founded in 2009. It specializes in the development and supply of high-quality reagents, kits, and drug discovery assay development services, primarily targeting the life science research community. Ubiquigent focuses on protein degradation and the ubiquitin signaling systems, providing services that support drug discovery efforts aimed at developing novel deubiquitylase (DUB) enzyme inhibitors. The company works closely with academic researchers and pharmaceutical scientists, aiding in the exploration of therapeutic applications for DUB modulators in areas with significant unmet medical needs. Ubiquigent is committed to generating intellectual property through its innovative drug discovery programs, which include optimizing compounds that target the ubiquitin cascade.

Almac Group is a contract development and manufacturing organization that provides a comprehensive array of services to pharmaceutical and biotech companies worldwide. Established over 40 years ago and privately owned, the company offers research and development, biomarker discovery, active pharmaceutical ingredient (API) manufacturing, formulation development, clinical trial supply, and commercial-scale manufacturing, among other services. With its headquarters in Craigavon, Northern Ireland, Almac has expanded its operations to various locations, including the UK, Ireland, the US, and Asia. The company employs over 4,500 staff and is committed to continuous investment in its offerings, which encompass biomarker and companion diagnostics, clinical trial data management, and biocatalytic API manufacture. Additionally, Almac Discovery, a division of the group, focuses on innovative oncology research and the early-stage development of novel cancer treatments in partnership with pharmaceutical companies.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

Oxford Heartbeat develops innovative medical device software designed to enhance the planning and execution of cardiovascular surgeries. The company's platform allows surgeons to visualize critical information about a patient's anatomy by providing insights into blood vessels, tissue, and bone structures. This advanced technology, which leverages predictive computations, big data, and artificial intelligence, enables medical professionals to rehearse procedures and select the most effective surgical scenarios tailored to individual patients. By improving surgical preparation, Oxford Heartbeat aims to reduce complication rates and associated healthcare costs while enhancing overall patient care. The company is currently conducting prospective clinical trials in NHS hospitals, supported by the UK government's AI in Health and Care Awards.

Vitamica Ltd is a diagnostic technology company based in Bristol, United Kingdom, founded in 2018 as a spin-out from the University of Bristol. The company specializes in rapid antimicrobial susceptibility testing (AST) that determines the effectiveness of antibiotics against pathogenic bacteria. By utilizing advanced optical technology, Vitamica's diagnostic method detects nanoscale fluctuations in live bacteria, providing clinicians with crucial information to make informed decisions regarding antibiotic treatment. With an expanding intellectual property portfolio, Vitamica aims to capitalize on opportunities in the healthcare, veterinary, and pharmaceutical sectors, positioning itself as a notable innovator in the field of antimicrobial susceptibility testing.

PulmonIR has been researching and developing technology to help detect and monitor lung disease including COPD and lung cancer.

Physiomics plc combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company’s lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical and clinical trials. This optimisation improves the efficacy of combinations and streamlines the drug development process.

AccuRx is a healthcare communication platform that facilitates seamless interaction between patients and healthcare professionals. The platform enables users to send SMS messages, conduct video consultations, manage appointment bookings, and distribute medical surveys. It also supports the organization of outpatient clinics, virtual wards, and follow-up pathways, enhancing the overall efficiency of primary care. With its adoption by 98% of GP practices and 50% of NHS trusts, AccuRx plays a crucial role in improving communication and collaboration in patient care, ensuring that all parties involved can connect easily and effectively.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, based in Stirling, United Kingdom. Established in 2011 to address the growing global demand for niche sterile manufacturing, the company provides filling and finishing services tailored to biotechnology and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis differentiates itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. By maintaining high standards of regulatory compliance, Symbiosis supports the evolving needs of its clients in the pharmaceutical sector.

Stratified Medicine Scotland Innovation Centre is based in the University of Glasgow’s Clinical Innovation Zone at the Queen Elizabeth University Hospital (QEUH) campus in Glasgow.SMS-IC is a unique consortium of partners, comprising NHS Scotland, four Scottish Universities(Glasgow, Edinburgh, Dundee and Aberdeen) and industrial partners across informatics and genomics (Aridhia Ltd and ThermoFisher Ltd).

Metrion Biosciences Ltd is a contract research organization based in Cambridge, United Kingdom, specializing in drug discovery services for pharmaceutical and bioscience clients globally. Established in 2015, the company provides a range of preclinical screening services, with a focus on ion channel screening, cardiac safety profiling, neuroscience assays, and translational assays. Metrion's platform offers skilled electrophysiology services in various formats, supporting medicinal chemistry optimization. The organization employs flexible business models, allowing clients to choose between fee-for-service and collaborative options, as well as access to integrated drug discovery services tailored to the specific needs of each program.

Oxford BioMedica is a biopharmaceutical company based in Oxford, United Kingdom, specializing in gene and cell therapy. It is recognized for its expertise in lentiviral vector technology, which allows for the integration of therapeutic genes into non-dividing cells, including neurons and retinal cells. The company operates in two main segments: Platform and Product. The Platform segment focuses on bioprocessing and development services for third parties, while the Product segment is dedicated to the clinical and preclinical development of gene and cell therapies targeting a range of diseases, particularly those affecting the ocular and central nervous system. Oxford BioMedica's product pipeline includes several candidates, such as OXB-302 for haematological tumors and OXB-203 for wet age-related macular degeneration, among others. The company has established partnerships with major pharmaceutical firms, including Novartis and Bristol Myers Squibb, to enhance its research and development efforts. Founded in 1995, Oxford BioMedica aims to transform treatment options for diseases with limited or no existing therapies.

Cobra Biologics is a leading international contract manufacturing organisation (CMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. Cobra has three GMP approved facilities in Sweden and the UK, each with expertise tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market. As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries. Cobra is a Contract Manufacturing Organisation (CMO) supporting the global life sciences industry in the development and manufacture of monoclonal antibodies (mAb), recombinant proteins, DNA, viruses, phage and cell line derived products and pharmaceuticals for clinical trials and commercial supply. Over 15 years of track record in producing biologics and pharmaceuticals for use in pre-clinical to Phase III clinical trials and commercial supply has given our people a unique knowledge base as both manufacturer and also as service providers for the global life sciences market. We offer a broad range of integrated and stand-alone development services, stretching from cell line development to the supply of investigational medicinal product for clinical trials and commercial market supply.

Domainex Ltd. is a biotechnology company based in Saffron Walden, United Kingdom, specializing in contract research and contract manufacturing services focused on drug discovery. Established in 2001, the company offers a comprehensive range of services including medicinal chemistry, computational chemistry, protein expression and purification, biochemical assay development, and DMPK analysis. Domainex also employs advanced technologies for hit identification and combinatorial domain hunting. The company is particularly noted for its work in developing innovative treatments for inflammatory diseases, such as DMXD-011, a small-molecule inhibitor targeting TBK1/IKKε/SIK2 for conditions like rheumatoid arthritis and lupus. Through its capabilities in biology and chemistry, Domainex aims to assist healthcare professionals in addressing complex drug discovery challenges, particularly in oncology and related fields.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

Spoonful of Sugar Ltd. specializes in providing evidence-based adherence solutions for healthcare providers and the life sciences industry. The company focuses on optimizing medication access and enhancing adherence through intelligent medicines engagement programs. By delivering tailored services, Spoonful of Sugar aims to improve stakeholder concordance and overall health outcomes. Their work involves consulting on medicines-related behavior, enabling clients to gain a deeper understanding of the factors that influence medication adherence. Through these initiatives, Spoonful of Sugar seeks to support both healthcare providers and the pharmaceutical industry in achieving better patient care.

Spirea Ltd. is a healthcare technology company based in Harrogate, United Kingdom, that specializes in developing antibody drug conjugates (ADCs) for cancer treatment. Founded in 2015, Spirea has created a smart polymer platform designed for the controlled delivery of drug combinations, thereby maximizing the clinical efficacy of therapies. The company's innovative approach to ADCs allows for a greater amount of drug payload to be specifically targeted to tumor cells, resulting in enhanced therapeutic effects while significantly minimizing side effects. This development enables healthcare providers to offer well-tolerated treatment options for a variety of cancers, ultimately aiming to improve the quality of life for patients.

Renephra Ltd. is a medical device company based in Manchester, United Kingdom, established in 2009. It specializes in developing innovative Transdermal Fluid Removal (TFR) technology aimed at addressing fluid overload and chronic conditions such as oedema and lymphoedema. The company's devices utilize a micro-needle system combined with negative pressure therapy to facilitate minimally invasive fluid removal from the skin. This technology targets significant clinical needs within vascular and oncology patients, representing a large and underserved market estimated at £1 billion globally. Having achieved proof of concept in human trials, Renephra is currently seeking funding to advance its device development and feasibility studies.

CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based on the culture of primary human hepatocytes in the company’s proprietary LiverChip platform. The HBV disease model, which is referred to as Quantum-B, is currently being deployed in drug discovery and research alliances with several leading pharmaceutical and biotech companies. Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next-generation organ-on-chips which will improve the quality of life for millions of people around the world by fast-tracking breakthrough therapies to market.

Xerion Healthcare Limited, founded in 2015 and based in Thame, United Kingdom, specializes in developing and commercializing innovative nanoparticle treatments aimed at improving cancer care. The company focuses on utilizing titanium dioxide nanoparticles, which are injected into tumors prior to standard radiotherapy. This method enhances the effectiveness of radiotherapy by amplifying the dose of free radicals generated by X-rays, allowing for more effective treatment of dense tumors. Xerion Healthcare is currently advancing its technology for head, neck, and pancreatic cancers, with the goal of improving patient outcomes while minimizing side effects associated with conventional cancer treatments.

Centauri Therapeutics is a biotechnology company focused on the discovery and development of innovative immunotherapeutics aimed at treating life-threatening diseases. The company employs its proprietary Alphamer technology, which utilizes chemically synthesized molecules to redirect naturally occurring antibodies towards specific pathogens, enhancing the body's immune response to fight infections. Centauri's approach features a dual mechanism of action: a moiety that directly targets cell surface antigens and a glycan effector domain that activates a robust pre-existing polyclonal immune response. This response facilitates cell death through mechanisms such as complement fixation, antibody-dependent cellular cytotoxicity, and phagocytosis by myeloid cells. Centauri has produced promising pre-clinical data, showcasing significant enhancements in complement fixation and opsonophagocytosis for both anti-bacterial and oncology therapeutics, along with in vivo proof of concept data across multiple infection models.

Activirosomes develops effective, safe and affordable vaccines and virotherapies.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

Oxford Heartbeat develops innovative medical device software designed to enhance the planning and execution of cardiovascular surgeries. The company's platform allows surgeons to visualize critical information about a patient's anatomy by providing insights into blood vessels, tissue, and bone structures. This advanced technology, which leverages predictive computations, big data, and artificial intelligence, enables medical professionals to rehearse procedures and select the most effective surgical scenarios tailored to individual patients. By improving surgical preparation, Oxford Heartbeat aims to reduce complication rates and associated healthcare costs while enhancing overall patient care. The company is currently conducting prospective clinical trials in NHS hospitals, supported by the UK government's AI in Health and Care Awards.

N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing and novel high value drugs with an unmet commercial or medical need . N4’s commercial strategy is to advance a pipeline of products through clinical proof of concept and then partner to take the products through the relevant regulatory pathway studies to regulatory approval.

BrainWaveBank has developed a first-in-class wearable electroencephalography (EEG) device to conveniently and non-invasively measure the mechanisms that underpin neurological disorders and therapies. Our platform can securely gather, store and analyse data from many thousands of users, building neurocognitive profiles of individuals and populations or demographic groups. This easy-to-scale and distributable approach will help clinical professionals to transform our understanding of brain health and develop the next generation of treatments. BrainWaveBank was founded in January 2015 and has offices in Belfast , Northern Ireland and Dublin, Ireland.

LIFNano Therapeutics, established in 2013 as a spin-out from the University of Cambridge, is a clinical-stage company dedicated to the development of targeted therapies for neurodegenerative diseases, particularly multiple sclerosis. The company specializes in utilizing nanotechnology to deliver the biologic Leukaemia Inhibitory Factor (LIF), aiming to repair damaged tissues, including neurons in the brain and spinal cord. By focusing on natural treatment options, LIFNano Therapeutics seeks to provide innovative solutions for patients suffering from multiple sclerosis and other inflammatory diseases affecting the brain and immune system.

Sarissa Biomedical, Ltd. specializes in the development and production of innovative biosensors aimed at measuring neuroactive chemicals for research and clinical diagnostic purposes. The company focuses on creating minimally invasive, microelectrode electrochemical sensors that accurately measure purines and other neurochemicals, serving as indicators of neurological activity and disorders. These biosensors are suitable for both in vitro and in vivo studies. Additionally, Sarissa Biomedical is developing a hand-held point-of-care diagnostic device that utilizes finger-prick blood samples to identify individuals experiencing strokes. Founded in 2002 and based in Coventry, the United Kingdom, Sarissa Biomedical markets its products in various regions, including the United Kingdom, United States, Canada, and Japan.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Genomics plc is focused on transforming healthcare through advanced genomic analysis. The company employs sophisticated methodologies to analyze large integrated datasets of genomic and phenotypic information, aiming to enhance understanding of human biology. By leveraging genetic inference technology, Genomics plc seeks to identify new drug targets for serious diseases and assess individual disease risk. Their analytical platform enables the exploration of genomic sequence data, providing valuable insights that support pharmaceutical companies in reducing risks associated with drug development. This approach not only aims to improve healthcare outcomes but also sets a standard for how organizations and patients can benefit from genomic data.